Delving into the Latest Updates on KL070002 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

ccdB

Action

inhibitors

Mechanism

ccdB inhibitors(Cytotoxic protein CcdB inhibitors)

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Advanced Malignant Solid Neoplasm

Originator Organization

Sichuan Kelun Botai Biomedicine Co., Ltd.

Active Organization-

Inactive Organization

Sichuan Kelun Botai Biomedicine Co., Ltd.

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

RegulationSpecial Review Project (China)

Login to view timeline

评估KL070002胶囊在晚期实体瘤患者中单次和多次给药后的安全性和耐受性，确定KL070002胶囊的剂量限制性毒性（DLT）和最大耐受剂量（MTD）；评估晚期实体瘤患者口服KL070002胶囊后的原型及相关代谢物药代动力学特征；观察KL070002胶囊在晚期实体瘤患者中的初步疗效。

[Translation]

To evaluate the safety and tolerability of KL070002 capsules after single and multiple administrations in patients with advanced solid tumors, determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of KL070002 capsules; to evaluate the pharmacokinetic characteristics of the prototype and related metabolites of KL070002 capsules after oral administration in patients with advanced solid tumors; and to observe the preliminary efficacy of KL070002 capsules in patients with advanced solid tumors.

Start Date26 Jun 2018

Sponsor / Collaborator

Sichuan Kelun Botai Biomedicine Co., Ltd.

100 Clinical Results associated with KL070002

Login to view more data

100 Translational Medicine associated with KL070002

Login to view more data

100 Patents (Medical) associated with KL070002

Login to view more data

100 Deals associated with KL070002

Login to view more data